Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review
Rio Uehara,Daisuke Obinata,Sho Hashimoto,Ken Nakahara,Hideaki Uchida,Tsuyoshi Yoshizawa,Junichi Mochida,Kenya Yamaguchi,Masakuni Sakaguchi,Yoshinari Ozawa,Fumi Mori,Katsuhiro Miura,Toshiyuki Ishige,Shinobu Masuda,Tomohiro Nakayama,Satoru Takahashi
DOI: https://doi.org/10.1097/md.0000000000037371
IF: 1.6
2024-03-13
Medicine
Abstract:Despite recent progress in treating castration-resistant prostate cancer (CRPC), some patients still have poor prognoses. One reason for changing cancer cells is their phenotypes, including transitioning to neuroendocrine prostate cancer (NEPC). Recently, a new subtype of prostate cancer called treatment-related NEPC (t-NEPC) was added to the revised World Health Organization classification of prostate cancer. [ 1 ] On the other hand, CRPC with BRCA mutations has been the focus of much research due to its unique genetic makeup and challenging prognosis. [ 2 ] A recent study showed that olaparib, a polyadenosine diphosphate-ribose polymerase (PARP) inhibitor, is a promising treatment option for CRPC with BRCA mutations, surpassing the efficacy of androgen receptor-signaling inhibitors. [ 2 ] These have opened up new treatment avenues for various malignancies; however, patients with t-NEPC and BRCA mutations are rare and the standard treatment is not established. In this report, we describe a unique case of t-NEPC with a BRCA2 mutation, highlighting the sustained effectiveness of olaparib treatment. Additionally, we conducted a review of literature on similar cases of t-NEPC with BRCA2 mutation treated with olaparib. This review aims to clarify the clinical features associated with BRCA2 mutations in t-NEPC and to explore potential treatment strategies.
medicine, general & internal